📰 Mark Frattini News
Mark Frattini News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Frattini. Real-time updates on events, politics, business and more.
June 4, 2024
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell
May 17, 2023
NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | May 17, 2023
May 17, 2023
NEW YORK, May 17, 2023 -- Cellectis , a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today presents clinical data... | June 12, 2023
May 11, 2023
BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL populationNEW YORK, May 11, 2023 -- Cellectis , a clinical-stage biotechnology company... | May 11, 2023
April 11, 2023
UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study is actively enrolling patients... | April 11, 2023
December 13, 2022
UCART22: anti-tumor activity observed in 60% of patients at DL3 using FCA lymphodepletionUCART123: 25% of patients at DL2 in the FCA arm achieved meaningful response; one patient experienced a... | December 13, 2022
November 3, 2022
ASH 2022 sponsored programs – UCART123 abstract selected for oral presentation & preclinical data on UCARTCS1 selected for poster presentation, in...
April 28, 2022
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
March 4, 2021
Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2020 Financial Results March 04, 2021 16:42 ET | Source: Cellectis Inc. Cellectis Inc. New York, New York, UNITED STATES Enrollment ongoing in 3 Cellectis-sponsored Phase 1 dose-escalation trials BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 7 leading US clinical centers Preliminary results from our Phase 1 BALLI-01 clinical stud...